Brown Advisory Inc. Acquires 43,034 Shares of Amgen, Inc. (AMGN)
Brown Advisory Inc. increased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 23.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 229,444 shares of the medical research company’s stock after buying an additional 43,034 shares during the period. Brown Advisory Inc.’s holdings in Amgen were worth $42,352,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the stock. Marco Investment Management LLC raised its holdings in Amgen by 4.6% during the 2nd quarter. Marco Investment Management LLC now owns 118,601 shares of the medical research company’s stock worth $21,893,000 after purchasing an additional 5,265 shares during the last quarter. British Airways Pensions Investment Management Ltd raised its holdings in Amgen by 0.8% during the 2nd quarter. British Airways Pensions Investment Management Ltd now owns 49,610 shares of the medical research company’s stock worth $9,158,000 after purchasing an additional 406 shares during the last quarter. Institute for Wealth Management LLC. raised its holdings in Amgen by 5.7% during the 2nd quarter. Institute for Wealth Management LLC. now owns 15,164 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 821 shares during the last quarter. Sand Hill Global Advisors LLC bought a new position in Amgen during the 2nd quarter worth approximately $237,000. Finally, Modera Wealth Management LLC raised its holdings in Amgen by 7.6% during the 2nd quarter. Modera Wealth Management LLC now owns 28,290 shares of the medical research company’s stock worth $5,222,000 after purchasing an additional 2,002 shares during the last quarter. Institutional investors and hedge funds own 77.20% of the company’s stock.
Several research firms have issued reports on AMGN. Oppenheimer restated a “buy” rating and set a $224.00 price target on shares of Amgen in a report on Tuesday, August 28th. Wells Fargo & Co restated a “neutral” rating and set a $197.00 price target on shares of Amgen in a report on Wednesday, August 29th. Jefferies Financial Group restated a “buy” rating and set a $220.00 price target on shares of Amgen in a report on Friday, August 24th. Morgan Stanley raised their price target on shares of Amgen from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Friday, July 13th. Finally, BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 11th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have issued a buy rating to the stock. Amgen has a consensus rating of “Hold” and a consensus price target of $202.76.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, beating the consensus estimate of $3.52 by $0.31. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 10.19% and a return on equity of 43.18%. Amgen’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.27 EPS. analysts forecast that Amgen, Inc. will post 13.95 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 7th. Shareholders of record on Friday, August 17th will be paid a dividend of $1.32 per share. The ex-dividend date is Thursday, August 16th. This represents a $5.28 dividend on an annualized basis and a yield of 2.68%. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $195.71, for a total transaction of $298,457.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
See Also: What is a Tariff?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.